IDEXX Laboratories Inc (IDXX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $55.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
IDEXX Laboratories Inc (IDXX) Earnings: Report Dates and Results
IDEXX Laboratories (IDXX) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, IDEXX Laboratories reported EPS of $3.98, above the $3.71 estimate. It beat the EPS estimate in each of the last 17 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IDXX has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.7% above the $3.08 reported for the quarter ended Dec 31, 2025.
IDXX Earnings Call
The latest IDXX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, IDXX beat 39 and missed 1. Revenue for the quarter ended Sep 30, 2026 was $1.21B, up 9.0% from $1.11B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.98 | $3.71 | $3.37 - $3.91 | +7.28% | Beat | +17.1% | 10 | 3 up, 7 down | Nov 2, 2026 | $1.21B |
| Jun 30, 2026 | $4.27 | $3.95 | $3.81 - $4.03 | +8.10% | Beat | +17.6% | 12 | 3 up, 3 down | Aug 4, 2026 | $1.22B |
| Mar 31, 2026 | $3.47 | $3.41 | $3.35 - $3.48 | +1.76% | Beat | +17.2% | 11 | 0 up, 1 down | May 5, 2026 | $1.14B |
| Dec 31, 2025 | $3.08 | $2.94 | $2.87 - $3.00 | +4.76% | Beat | +17.6% | 10 | 1 up, 0 down | Feb 2, 2026 | $1.09B |
| Sep 30, 2025 | $3.40 | $3.15 | $2.99 - $3.18 | +7.94% | Beat | +21.4% | 11 | 1 up, 0 down | Nov 3, 2025 | $1.11B |
| Jun 30, 2025 | $3.63 | $3.30 | $3.26 - $3.35 | +10.00% | Beat | +20.2% | 9 | 3 up, 0 down | Aug 4, 2025 | $1.11B |
| Mar 31, 2025 | $2.96 | $2.84 | $2.77 - $2.95 | +4.23% | Beat | +5.3% | 9 | 1 up, 4 down | May 1, 2025 | $998.43M |
| Dec 31, 2024 | $2.62 | $2.40 | $2.35 - $2.47 | +9.17% | Beat | +12.9% | 9 | 0 up, 0 down | Feb 3, 2025 | $954.29M |
| Sep 30, 2024 | $2.80 | $2.69 | $2.64 - $2.71 | +4.09% | Beat | +10.7% | 9 | 0 up, 0 down | Oct 31, 2024 | $975.54M |
| Jun 30, 2024 | $3.02 | $2.87 | $2.84 - $2.97 | +5.23% | Beat | +13.1% | 9 | 1 up, 0 down | Aug 6, 2024 | $1.00B |
| Mar 31, 2024 | $2.81 | $2.67 | $2.60 - $2.75 | +5.24% | Beat | +10.2% | 8 | 1 up, 0 down | May 1, 2024 | $964.10M |
| Dec 31, 2023 | $2.32 | $2.12 | $2.08 - $2.19 | +9.43% | Beat | +13.2% | 8 | 4 up, 0 down | Feb 5, 2024 | $901.60M |
| Sep 30, 2023 | $2.53 | $2.37 | $2.28 - $2.43 | +6.75% | Beat | +17.7% | 8 | 0 up, 0 down | Nov 1, 2023 | $915.53M |
| Jun 30, 2023 | $2.67 | $2.47 | $2.39 - $2.60 | +8.10% | Beat | +71.2% | 9 | 0 up, 0 down | Aug 1, 2023 | $943.63M |
| Mar 31, 2023 | $2.55 | $2.43 | $2.31 - $2.56 | +4.94% | Beat | +12.3% | 9 | 1 up, 0 down | May 2, 2023 | $900.20M |
| Dec 31, 2022 | $2.05 | $1.92 | $1.85 - $2.01 | +6.77% | Beat | +8.5% | 9 | 3 up, 0 down | Feb 6, 2023 | $828.57M |
| Sep 30, 2022 | $2.15 | $2.04 | $1.96 - $2.08 | +5.39% | Beat | +5.9% | 10 | 1 up, 2 down | Nov 1, 2022 | $841.66M |
| Jun 30, 2022 | $1.56 | $1.63 | $1.49 - $2.35 | -4.29% | Miss | -33.3% | 10 | 1 up, 1 down | Aug 2, 2022 | $860.55M |
| Mar 31, 2022 | $2.27 | $2.25 | $2.15 - $2.37 | +0.89% | Beat | -3.4% | 9 | 1 up, 1 down | May 4, 2022 | $836.55M |
| Dec 31, 2021 | $1.89 | $1.72 | $1.65 - $2.01 | +9.88% | Beat | +7.4% | 8 | 0 up, 0 down | Feb 2, 2022 | $801.09M |
| Sep 30, 2021 | $2.03 | $1.91 | $1.66 - $2.07 | +6.28% | Beat | +20.1% | 8 | N/A | Nov 2, 2021 | $810.42M |
| Jun 30, 2021 | $2.34 | $2.04 | $1.90 - $2.17 | +14.71% | Beat | +36.0% | 8 | N/A | Jul 30, 2021 | $826.14M |
| Mar 31, 2021 | $2.35 | $1.72 | $1.60 - $1.80 | +36.63% | Beat | +82.2% | 8 | N/A | May 4, 2021 | $777.71M |
| Dec 31, 2020 | $1.76 | $1.39 | $1.19 - $1.53 | +26.62% | Beat | +69.2% | 8 | N/A | Feb 2, 2021 | $720.94M |
| Sep 30, 2020 | $1.69 | $1.44 | $1.35 - $1.49 | +17.36% | Beat | +36.3% | 7 | N/A | Oct 29, 2020 | $721.79M |
| Jun 30, 2020 | $1.72 | $1.17 | $0.89 - $1.40 | +47.01% | Beat | +20.3% | 7 | N/A | Jul 31, 2020 | $637.59M |
| Mar 31, 2020 | $1.29 | $1.20 | $1.06 - $1.26 | +7.50% | Beat | +10.3% | 7 | N/A | Apr 30, 2020 | $626.34M |
| Dec 31, 2019 | $1.04 | $0.90 | $0.87 - $0.93 | +15.56% | Beat | +6.1% | 7 | N/A | Jan 31, 2020 | N/A |
| Sep 30, 2019 | $1.24 | $1.14 | $1.12 - $1.17 | +8.77% | Beat | +18.1% | 8 | N/A | Oct 31, 2019 | $605.30M |
| Jun 30, 2019 | $1.43 | $1.37 | $1.35 - $1.39 | +4.38% | Beat | +16.3% | 7 | N/A | Aug 1, 2019 | $1.24B |
| Mar 31, 2019 | $1.17 | $1.06 | $0.97 - $1.08 | +10.38% | Beat | +15.8% | 6 | N/A | May 1, 2019 | $576.06M |
| Dec 31, 2018 | $0.98 | $0.91 | $0.89 - $0.92 | +7.69% | Beat | +27.3% | 6 | N/A | Feb 1, 2019 | $549.39M |
| Sep 30, 2018 | $1.05 | $0.97 | $0.93 - $0.99 | +8.25% | Beat | +32.9% | 7 | N/A | Nov 1, 2018 | $545.45M |
| Jun 30, 2018 | $1.23 | $1.17 | $1.14 - $1.21 | +5.13% | Beat | +29.5% | 9 | N/A | Aug 1, 2018 | $580.75M |
| Mar 31, 2018 | $1.01 | $0.92 | $0.90 - $0.99 | +9.78% | Beat | +31.2% | 10 | N/A | May 4, 2018 | $537.66M |
| Dec 31, 2017 | $0.77 | $0.73 | $0.70 - $0.75 | +5.48% | Beat | +32.8% | 8 | N/A | Feb 1, 2018 | $506.12M |
| Sep 30, 2017 | $0.79 | $0.74 | $0.73 - $0.76 | +6.76% | Beat | +27.4% | 9 | N/A | Oct 31, 2017 | $491.98M |
| Jun 30, 2017 | $0.95 | $0.85 | $0.82 - $0.88 | +11.76% | Beat | +28.4% | 9 | N/A | Aug 1, 2017 | $508.94M |
| Mar 31, 2017 | $0.77 | $0.60 | N/A | +28.33% | Beat | +51.0% | N/A | N/A | Apr 28, 2017 | $462.02M |
| Dec 31, 2016 | $0.58 | $0.51 | N/A | +13.73% | Beat | +20.8% | N/A | N/A | Feb 2, 2017 | $443.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $13.07, up 16.2% from the year before. It was $2.45 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $13.07 | +16.2% |
| Dec 31, 2024 | $11.25 | +11.7% |
| Dec 31, 2023 | $10.07 | +25.4% |
| Dec 31, 2022 | $8.03 | -6.7% |
| Dec 31, 2021 | $8.61 | +33.3% |
| Dec 31, 2020 | $6.46 | +32.4% |
| Dec 31, 2019 | $4.88 | +14.3% |
| Dec 31, 2018 | $4.27 | +30.2% |
| Dec 31, 2017 | $3.28 | +33.9% |
| Dec 31, 2016 | $2.45 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,100 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,069 | 10 | |
| 2026Q2 | Jun 30, 2026 | 8,185 | 10 | |
| 2026Q1 | Mar 31, 2026 | 8,355 | 11 | |
| 2025Q4 | Dec 31, 2025 | 8,807 | 10 | |
| 2025Q3 | Sep 30, 2025 | 6,646 | 11 | |
| 2025Q2 | Jun 30, 2025 | 7,824 | 11 | |
| 2025Q1 | Mar 31, 2025 | 8,270 | 11 | |
| 2024Q4 | Dec 31, 2024 | 7,358 | 10 |
2026Q3 Earnings Call
Opening remarks
Andrew Emerson CFO Good morning. I am pleased to take you through our third quarter results and provide an updated outlook for our full-year 2026 financial expectations. During the third quarter, IDEXX delivered outstanding financial results, driven by strong global execution, the expanding impact of IDEXX Innovations, and continued progress in increasing the medically relevant use of diagnostics across our companion animal business. We also advanced our software, data, and AI capabilities through the acquisition of ezyVet. Revenue increased 10% organically, supported by 11% organic growth in CAG Diagnostics recurring revenues, reflecting nearly 14% gains in international regions and nearly 10% growth in the U.S. We saw strong demand for diagnostic solutions, including IDEXX Innovations, as demonstrated by premium instrument placements of nearly 5.8 thousand units, with over 1.9 thousand IDEXX InVue Dx analyzers. Operating performance was excellent, with comparable operating margin gains of approximately 60 basis points year over year, led by improvement in gross margin while making ongoing investments in the business, including costs related to the ezyVet acquisition. Strong operating profit gains enabled $4.10 per share in the quarter, an increase of 18% as reported and 22% on a comparable basis. Strong third-quarter performance supports an increase to our full-year revenue outlook. We are raising our full-year revenue range to $4.741 billion to $4.767 billion, a $32 million increase at the midpoint, reflecting strong third-quarter performance and approximately $5 million of revenue from ezyVet. Our updated full-year overall organic revenue growth outlook is 9.3% to 10%, with organic CAG Diagnostics recurring revenue growth of 10.3% to 11%. These ranges represent an increase of approximately 60 basis points at the midpoint, along with tightening the low end of the range as we enter the final quarter of the year. We also increased our full-year EPS outlook to $14.96 to $15.16 per share, an $0.25-per-share increase at the midpoint, reflecting 15% to 16% comparable EPS growth while observing near-term dilution related to the ezyVet acquisition. We will provide further details on our updated 2026 financial expectations later in my comments. Let's begin with a review of our third-quarter results. Third-quarter organic revenue growth of 10% was driven by 10% CAG revenue gains, 8% growth in our water business, and 3% growth in LPD. Strong CAG results were driven by CAG Diagnostics recurring revenue growth of 11% organically, which was volume-led, reflecting strong execution and contributions from innovations, and included approximately 4% global net price improvement. Demand for IDEXX diagnostic solutions remains high, and we have realized benefits from net new customer gains, expansion of our premium instrument installed base, and increased utilization of IDEXX Innovations. U.S.
Frequently Asked Questions About IDXX
When is IDEXX Laboratories's next earnings date?
IDEXX Laboratories's next earnings report is expected for Feb 1, 2027.
Did IDXX beat earnings estimates last quarter?
Yes. IDEXX Laboratories reported EPS of $3.98 for the quarter ended Sep 30, 2026, above the $3.71 estimate, a 7.28% surprise.
What EPS do analysts expect from IDXX next quarter?
The consensus EPS estimate for IDEXX Laboratories for the quarter ending Dec 31, 2026 is $3.38 from 15 analysts, with estimates from $3.19 to $3.57.
How often does IDXX beat earnings estimates?
IDEXX Laboratories beat the EPS estimate in each of the last 17 quarters, with an average surprise of +6.42%.
IDXX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts